Skip to main content

Table 1 Baseline characteristics of adult severe sepsis patients with purpura fulminans, meningitis, or meningococcal disease

From: Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies

Baseline characteristics1

No PF, MEN, or MD n = 3,907 (816 PLC)

PF, MEN, or MD n = 189 (24 PLC)

PF n = 77 (5 PLC)

MEN n = 128 (21 PLC)

MD n = 92 (10 PLC)

Demographics and disease severity

     

   Age (years), mean ± SD

60.3 ± 16.5

44.4 ± 19.6

34.6 ± 14.4

48.2 ± 20.4

34.9 ± 16.1

   Male (%)

57.8

53.4

58.4

53.1

50.0

   Caucasian (%)

86.8

91.0

92.2

91.4

89.1

   Organ dysfunctions, median; q1-q3

3.0; 2.0–3.0

2.0; 1.0–4.0

3.0; 2.0–4.0

2.0; 1.0–3.0

2.0; 2.0–4.0

   First organ dysfunction to infusion (h), mean ± SD

22.6 ± 13.0

18.3 ± 13.2

13.5 ± 11.8

18.5 ± 13.4

14.9 ± 11.3

   APACHE II score, mean ± SD

23.2 ± 7.6

22.6 ± 8.1

22.3 ± 7.8

22.0 ± 7.9

21.9 ± 7.8

   GCS score, mean ± SD

12.2 ± 3.8

10.3 ± 4.1

11.8 ± 3.8

9.8 ± 4.0

11.2 ± 4.1

Underlying comorbidities

     

   Congestive cardiomyopathy (%)

5.7

0

0

0

0

   COPD (%)

19.4

3.1

0

4.0

1.3

   Diabetes (%)

21.0

9.9

2.0

11.3

5.1

   Hypertension (%)

36.7

18.0

6.1

20.2

7.7

   Liver disease (%)

2.9

2.5

4.1

2.4

2.6

   Cancer (%)

16.3

7.5

2.0

8.1

5.1

   Myocardial infarction (%)

11.6

1.9

0

2.4

0

   Pancreatitis (%)

3.7

1.2

0

1.6

1.3

   Recent trauma (%)

3.9

1.9

4.1

1.6

1.3

   Recent surgery (%)

35.5

1.9

4.1

1.6

1.3

Coagulation biomarkers

     

   Protein C level (%), median; q1-q3

46; 30–64

47; 30–67

30; 20–45

54; 38–74

40; 27–53

   Platelet count, median; q1-q3

172; 105–249

91; 45–142

59; 35–95

119; 65–159

70; 34–121

   APTT (s), median; q1-q3

41; 34–50

44; 35–55

48; 41–63

40; 34–49

48; 38–62

   PT (s), median; q1-q3

18; 15–21

17; 15–22

17; 14–23

17; 15–21

19; 16–23

Cardiovascular and respiratory measures

     

   Vasopressor (%)

69.6

60.1

76.6

47.2

72.5

   Ventilator (%)

79.3

79.8

80.5

76.4

76.9

   Cardiovascular study entry criteria (%)

78.8

68.3

77.6

64.5

79.5

   Respiratory study entry criteria (%)

80.5

57.8

59.2

54.0

47.4

  1. 1Patients with missing data were excluded from this analysis. APACHE II, Acute Physiology and Chronic Health Evaluation II; APTT, activated partial thromboplastin time; COPD, chronic obstructive pulmonary disease; GCS, Glasgow Coma Scale; MD, meningococcal disease; MEN, meningitis; PF, purpura fulminans; PLC, placebo; PT, prothrombin time.